Dihydroartemisinin enhances VEGFR1 expression through up-regulation of ETS-1 transcription factor

Na Niu1,#, Changmei Yu2,3,#, Liqun Li3, Qiang Liu3, Wenqian Zhang4, Kaili Liang5, Youming Zhu5, Jing Li5, Xia Zhou6, Jinbao Tang2,3,*, Ju Liu3,*,

1. Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, Shandong, China 250021
2. College of Pharmacy, Weifang Medical University, 7166 Baotong West Street, Weifang, Shandong China 261053
3. Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan, Shandong China 250014
4. College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
5. College of Chemistry, Shandong Normal University, 88 Wenhua East Road, Jinan, Shandong China 250014
6. Department of Rehabilitation Medicine, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

# These authors contributed equally to the work

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2018.01.22; Accepted: 2018.07.17; Published: 2018.09.08

Abstract

Angiogenesis is required for tumor growth. Dihydroartemisinin (DHA), a the effective anti-malarial derivative of artemisinin, demonstrated potent anti-angiogenic activities that closely related to the regulation of vascular endothelial growth factor (VEGF) signaling cascade. VEGF receptor 1 (VEGFR1), a receptor in endothelial cells (ECs), coordinately regulate angiogenic activity triggered by ligand-receptor binding. Here we aimed to explore the effects of DHA on VEGFR1 expression in ECs. We found that DHA significantly increases VEGFR1 expression in human umbilical vein endothelial cells (HUVECs). In addition, DHA significantly upregulates the level of V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1 (ETS-1), a transcriptional factor which binds to the human VEGFR1 promoter. ChIP assay showed that DHA increases ETS-1 binding to the -52 ETS motif on the VEGFR1 promoter. Knockdown of ETS-1 by RNA interference abolished DHA-induced increase of VEGFR1 expression. Taken together, we demonstrated that DHA elevates VEGFR1 expression via up-regulation of ETS-1 transcription in HUVECs.

Key words: dihydroartemisinin, angiogenesis, endothelial cells, VEGFR1, ETS-1

Introduction

Angiogenesis refers to the form of new vascular network by the proliferation and migration from the original vascular endothelial cells [1]. Angiogenesis is essential both in the adult new blood vessel formation and in embryogenesis, while abnormal angiogenesis is related to certain pathological states such as cancer [2, 3]. During cancer growth, newly formed blood vessels are required to provide nutrients and oxygen, and remove the waste products [3, 4].

Among the regulators of angiogenesis, VEGF is the most potent stimulator in physiological and pathological situations [5, 6]. To promote angiogenesis, VEGF acts through its receptor VEGFR2, which is highly expressed in ECs [7-9]. VEGFR1, another receptor of VEGF, is considered to be a ‘decoy’ receptor which isolates VEGF and reduces its incorporation to VEGFR2 [10-12]. Previous studies suggested that VEGFR1 suppresses the pro-angiogenic signals induced by VEGFR2 in ECs [13]. In addition, the soluble VEGFR1 which carries only the extracellular domain, is considered to be a natural inhibitor of VEGF-A [7].

Dihydroartemisinin (DHA) is a semi-synthetic derivative of artemisinin, which is extracted from Chinese herb Artemisia annua [14, 15]. Like other artemisinin derivatives, DHA displayed strong...
anti-inflammatory and anti-angiogenic activities [16-18]. Although DHA have a positive role in angiogenesis in zebrafish [19], it suppressed the growth, proliferation, migration, and tube formation of mammalian ECs, which are essential processes in angiogenesis [20-22]. In addition, DHA inhibited VEGF expression in cancer cells and reduced VEGF binding to its receptors in HUVECs [18, 23]. However, the role and mechanisms by which DHA affects VEGFR1 expression in ECs have not been studied.

ETS-1 is a member of the ETS transcriptional factor family which contains about 30 related proteins and a basic 80-90 aa DNA-binding domain [24]. As a transcription factor, ETS-1 is highly expressed in vascular system [25, 26]. In ECs, ETS-1 regulates downstream target genes including Tie1, Tie2, MMPs, p53 and VEGFRI [27-30]. On the VEGFRI promoter, ETS-1 binds to a conserved ETS responsive element between -49 and -52 region to promote VEGFR1 expression [31].

In this study, we reported that DHA significantly upregulates the expression of VEGFRI and ETS-1 in HUVECs. ChIP assays validated that the binding of ETS-1 on the VEGFRI promoter was significantly increased by DHA treatment. In addition, knockdown of ETS-1 eliminates DHA-induced expression of VEGFRI. These results indicated that DHA elevates VEGFR1 expression via up-regulation of ETS-1 in HUVECs.

Materials and Methods

Cell culture

HUVECs were obtained from Lonza (Basel, Switzerland) and cultured in DMEM (Corning, NY, USA) with 10% FBS (Lonza), 100 IU/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA). HUVECs were treated with DHA (Sigma-Aldrich) for different time points (0, 1, 6, 12, 24 h) or concentrations (0, 5, 10, 25, 50, 100 μM).

Western blotting

After treatment with DHA, HUVECs were lysed in RIPA lysis buffer with 0.1% SDS, 1 mg/ml leupeptin and 1 mM PMSF on ice. Proteins were quantified by BCA assay (Bio-Rad, Hercules, CA, USA). The protein samples were loaded and separated on a 8% SDS-polycrylamide gel, then electroblotted onto the PVDF membranes. The membranes were blocked 1 h in 5% skim milk in TBS-T (TBS containing 0.05% Tween-20), and then incubated with the primary antibody at 4°C overnight. The primary antibodies include anti-VEGFR1 antibody (Abcam, Cambridge, MA, USA), anti-ETS-1 antibody (Abcam) and anti-β-actin antibody (Sigma-Aldrich). The membranes were washed in TBS-T, and incubated with a HRP-linked goat anti-rabbit secondary antibody (Proteintech, Chicago, IL, USA) for 2 h at room temperature. The protein bands were visualized with an ECL kit (Millipore, Billerica, MA, USA).

RNA extraction and quantitative real-time PCR(qRT-PCR)

Total RNA of HUVECs was isolated using Trizol (Invitrogen, Carlsbad, CA, USA), and the cDNAs was generated from the reverse transcription by the RevertAid First Strand cDNA Synthesis Kit (ThermoFisher, Grand Island, NY, USA). Then the mRNAs levels were evaluated by qRT-PCR executed by a Applied Biosystems PCR System (Waltham, MA, USA) with SYBR supermix (TaKaRa Biotechnology, Shiga, Japan) and following the thermocycling conditions: 94°C 1 min; 95°C 1 min; 95°C 12 s, 62°C 1 min; 40 cycles from step 3 to 4. The primers are as follows: VEGFRI: sense, 5'-TG GCCATCATACTAAGGA GCACCTC-3'; anti-sense, 5'-GAACCTGCTGATGCG CACTG-3'; ETS-1: sense, 5'-TTCTACTAAAGACA GCAAC-3'; anti-sense, 5'-GTCCTACAAAAGATC TG-3'; β-actin: sense, 5'-TGCCGACAGGATGCAG AA-3'; anti-sense, 5'-GCCATCCACACCGAGTA CT-3'. Results was normalized against β-actin.

Immunofluorescence (IF)

HUVECs were grown fluency on cover glass. After DHA treatment, 4% paraformaldehyde was added to fix the cells. Then the cells were penetrated with Triton X-100 (0.1%) for 10 min and blocked with 5% BSA. Proteins were labeled with primary antibody against VEGFR1 (Abcam) at 4°C overnight and an Alex-546 labelled anti-rabbit IgG secondary antibody (Molecular Probes, Eugene, OR, USA) for 1 h at room temperature. The cell nucleus was stained with DAPI (ThermoFisher). Positive staining were detected using a fluorescence microscopy (Olympus, Tokyo, Japan).

Chromatin immunoprecipitation (ChIP)

A ChIP assay Kit (Millipore) was used as previously described [32]. HUVECs were exposed to 1% paraformaldehyde for 10 min to achieve in vivo crosslinking, then the crosslinked DNA were sheared to 200-1000 bp fragments by sonication. The chromatin fragments were immunoprecipitated with antibodies against ETS-1 (Abcam) and IgG (Millipore) using protein A/G agrose beads. The immunoprecipitated gDNA was enriched by centrifuging and purified by Phenolic chloroform isoomyl alcohol (25:24:1). The immunoprecipitated fragments of the VEGFRI promoter were amplified by PCR. The primers are as follows: forward,
Transfection of siRNAs was performed when HUVECs were reached 60% confluent using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Briefly, transfection reagent was mixed with siRNAs (Genepharma, Shanghai, China) with Opti-MEM (Invitrogen) separately. The mixture was incubated for 20 min and added into the cell culture. The cells were collected 48 h later. The following siRNAs were used: ETS-1 siRNA: sense, 5'-AUAGAGAGCUACG AUAGUUdT-3'; anti-sense, 5'-AACUAUCGUAGC UCUCUAudTT-3'; control siRNA: sense, 5'-UUCUC CGAACGUGUCACGUTT-3'; anti-sense, 5'-ACGUG ACACGUUCCGAGAATT-3'.

**Statistical analysis**

Statistical significance was evaluated with paired-sample t-test by using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). p<0.05 was considered significant.

**Results**

**The effects of DHA on VEGFR1 expression in ECs**

HUVECs were treated with DHA at different dose and time course. We found that DHA remarkably increased the mRNA (Fig. 1A) and protein level (Fig. 1B) of VEGFR1 at a concentration of 50 µM and 100 µM. By treatment with 50 µM DHA, the mRNA and protein level of VEGFR1 was significantly increased in a time-dependent manner (Fig. 1C, D). Immunofluorescence staining with VEGFR1 antibody showed that the VEGFR1 expression on the EC membrane was remarkably increased by DHA treatment (Fig. 1E). Together, DHA increases VEGFR1 expression in HUVECs.
The effects of DHA on ETS-1 expression in ECs

Because ETS-1 is a major regulator of VEGFR1 [33, 34], we next investigated the effects of DHA on expression of ETS-1. qRT-PCR analysis showed that the ETS-1 mRNA expression levels were significantly increased by DHA treatment at 50 µM and 100 µM for 24 h (Fig. 2A). Western blot analysis showed a similarly pattern of increase of ETS-1 protein levels by 50 µM and 100 µM DHA treatment (Fig. 2B). At a concentration of 50 µM, DHA significantly increase the mRNA and protein levels of ETS-1 after 12 h and 24 h treatment (Fig 2C, D). These results indicated ETS-1 expression is enhanced during DHA treatment in HUVECs.

DHA enhances ETS-1 binding to the VEGFR1 promoter

Previously studies reported that the promoter of VEGFR1 gene contains ETS binding motifs [29, 31, 34]. To examine the effects of DHA on the interactions between ETS-1 and VEGFR1 promoter, HUVECs were treated with 50 µM DHA for 24 h and collected for ChIP assay. As shown on Fig. 3, ETS-1 binds to -52 ETS motif on the VEGFR1 promoter (Fig. 3A) and DHA further enhanced the binding of ETS-1 to the motif (p<0.05)(Fig. 3B).

Knockdown of ETS-1 eliminates DHA-induced expression of VEGFR1 in ECs

To confirm the role of ETS-1 in DHA induced VEGFR1 expression, ETS-1 were knocked down in HUVECs by siRNA interference. Transfection of
ETS-1 siRNA in HUVECs reduced both ETS-1 (P<0.01) (Fig. 4A) and VEGFR1 transcription (P<0.05) (Fig. 4B), and induced measurable decrease of ETS-1 (Fig. 4C) and VEGFR1 protein (Fig. 4D). Next, HUVECs with ETS-1 siRNA transfection were treated with 50 µM DHA for 24 h. In the ETS-1-silenced HUVECs, no increase in VEGFR1 mRNA (Fig. 4E) and protein (Fig. 4F) was observed after DHA treatment. Therefore, DHA-induced elevation of VEGFR1 expression is mediated by ETS-1.

**Discussion**

DHA is an effective anti-malarial agent with few side effects [15, 20]. Recent studies revealed a potent anti-tumor and anti-angiogenic activity of DHA [35, 36]. On cellular level, DHA exerted a significant inhibitory effect on apoptosis, migration and tube-like formation of ECs [37]. Several signaling cascades including NF-κB, PKC, ERK, JNK, and p38 MAPK pathway have been reported to mediate the effects of DHA [38-42]. For example, DHA activates JNK signaling pathway and then increases the expression of cyclooxygenase-2 and matrix metalloproteinase-13 (MMP-13) [43]. Moreover, DHA plays a negative role in the expression of hypoxia inducible factor (HIF)-1α, angiogenic mediators VEGF, MMP9, MMP11, and collagens [30, 44]. Structurally, DHA may bind to VEGF and its receptors [45]. Although dozens of papers have been published regarding the role of DHA on endothelial cell function, to date the effects of DHA on VEGFR1 expression in ECs have not been reported. In this study, we found that transcriptional factor ETS-1 mediates dihydroartemisinin-induced VEGFR1 expression. This novel finding was validated by mRNA and protein expression analyses, siRNA interference and examination of protein-DNA interactions.

VEGFR1 is one of the major regulators in vascular development and angiogenesis [7, 46]. The responses of VEGFR1 are influenced by the binding of ligands and the indirectly interaction with VEGFR2 [7, 29]. Loss of VEGFR1 increases VEGFR2 phosphorylation and activity, resulting in vessel overgrowth [47, 48]. Overexpression of VEGFR1 suppresses VEGFR2-mediated EC proliferation [13, 49]. In addition, VEGFR1 directly mediates a series of signal responses during angiogenesis and might prevent tumor growth [48]. In this study, we demonstrated that DHA treatment significantly enhances the expression of VEGFR1, which may suppresses VEGFR2-mediated pro-angiogenic responses. Therefore, our study provided a novel mechanism of the anti-angiogenic effect of DHA.

ETS-1 is a master regulator of endothelial gene transcription [50]. The transcriptional regulation of VEGFR1 by ETS-1 during embryonic or tumorous angiogenesis has been systematically studied [33, 34]. Binding of ETS-1 on -52 site activates VEGFR1 expression [51]. Our results showed that DHA significantly upregulates the expression of ETS-1 in HUVECs. ChIP assay also showed that DHA increases ETS-1 binding to the -52 ETS motif on the
VEGFR1 promoter. In addition, knockdown of ETS-1 abolished DHA-induced VEGFR1 expression. To our knowledge, this is the first study which validated the functional relevance between DHA and ETS-1. This suggests that ETS-1 as a novel mediator for the cellular functions of DHA and other artemisinin derivatives.

Although VEGFR-1 is highly expressed in ECs, it has also been detected in monocyte/macrophages, hematopoietic stem cells, and a subset of epithelial cancer cells [52, 53]. In other types of cells, VEGFR-1 also involves in regulation of cellular functions, e.g., it supports the growth and survival of human breast carcinoma [53]. ETS-1 is widely expressed in most cell types, and facilitates malignant transformation and tumour progression [54]. Therefore, ETS-1-regulated VEGFR-1 expression might exist in non-endothelial cells, which could also be effected by DHA treatment. Further studies are needed to explore the role of DHA on VEGFR-1 expression in non-endothelial cells, particularly in tumor cells.

In this study, we demonstrated that DHA induces VEGFR1 expression by up-regulating ETS-1 transcription factor. This is a novel mechanism contributing towards the effect of DHA on endothelium, and helps explore its clinical applications in chemotherapy.

Abbreviations

BMP1: Bone Morphogenetic Protein1; ChIP: Chromatin immunoprecipitation; DHA: dihydroartemisinin; ECs: endothelial cells; ETS-1: V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1; HIF-1α: hypoxia-inducible factor-1α; HUVECs: human umbilical vein endothelial cells; MMPs: matrix metalloproteinases; NF-κB: nuclear Factor-κB; PKC: protein kinase C; PVDF: polyvinylidene fluoride; p38 MAPK: p38 mitogen-activated protein kinase; siRNA: small interference RNA; VEGF: vascular endothelial growth factor; VEGFR1: vascular endothelial growth factor receptor 1; VEGFR2: vascular endothelial growth factor receptor 2.

Acknowledgements

This study was supported by the grants from Traditional Chinese Medicine Research Projects of Shandong Province (2015-285), The Key Science and Technology Research Plan of Shandong Province (2017CFSF218037), Natural Science Foundation of Shandong Province (ZR2014HQ058, ZR2014HM043) and Shandong Taishan Scholarship (Ju Liu).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Risau W. Mechanisms of angiogenesis. Nature. 1997; 386: 671-4.
2. Costa C, Soares R, Schmitt F. Angiogenesis: now and then. APFMS : acta pathologica, microbiologica, et immunologica Scandinavica. 2004; 112: 402-12.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature medicine. 1995; 1: 27-31.
4. Gao P, Niu N, Wei T, Tozawa H, Chen X, Zhang C, et al. The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget. 2017; 8: 69139-61.
5. Bjornsdal MA, Cao R, Burton JB, Brakenheim E, Religa P, Galler D, et al. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res. 2003; 63: 3059-71.
6. Takuwa N, Du W, Kaneko E, Okamoto Y, Yoshioka K, Takuwa Y. Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde. Am J Cancer Res. 2011; 1: 460-81.
7. Olsson AK, Dimberg, A, Kreueger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006; 7: 599-71.
8. Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Tamayo T. Expression of ETS-1 cooperatively to the palindromic Ets-binding sites in the p53 promoter. J Biol Chem. 2008; 283: 25404-13.
30. Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Sakaguchi H, et al. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology. 2004; 66: 420-8.

31. Morishita K, Johnson DE, Williams LT. A novel promoter for vascular endothelial growth factor receptor (Flt-1) that confers endothelial-specific gene expression. The Journal of biological chemistry. 1995; 270: 27948-53.

32. Xu Y, Pan S, Liu J, Dong F, Cheng Z, Zhang J, et al. GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature. Oncotarget. 2017; 8: 110517-29.

33. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, et al. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Annals of the New York Academy of Sciences. 2000; 902: 201-5; discussion 5-7.

34. Valley MM, Hugel A, Huang HJ, Cavenne WK, Wisteler OD, Pietsch T, et al. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neangiogenesis. Cancer Res. 1999; 59: 5608-14.

35. Dong F, Zhou X, Li C, Yan S, Deng X, Cao Z, et al. Dihydroartemisinin targets VEGFR2 via the NF-kappaB pathway in endothelial cells to inhibit angiogenesis. Cancer biology & therapy. 2014; 15: 1479-88.

36. Wei T, Liu J. Anti-angiogenic properties of artemisinin derivatives (Review). Int J Mol Med. 2017; 40: 972-8.

37. Wang J, Guo Y, Zhang BC, Chen ZT, Gao JF. Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. Pharmacology. 2007; 80: 207-18.

38. Hwang YP, Yun HJ, Kim HC, Han EH, Lee GW, Jeong HK. Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. Biochem Pharmacol. 2010; 79: 1714-26.

39. Cheng C, Ho WE, Goh PY, Guan SP, Kong LR, Lai WQ, et al. Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PLoS One. 2011; 6: e20932.

40. Guo L, Dong F, Hou Y, Cai W, Zhou X, Huang AL, et al. Dihydroartemisinin inhibits vascular endothelial growth factor-induced endothelial cell migration by a p38 mitogen-activated protein kinase-indepedent pathway. Exp Ther Med. 2014; 8: 1707-12.

41. Dong F, Tian H, Yan S, Li L, Dong X, Wang F, et al. Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway. International journal of molecular medicine. 2015; 35: 1381-7.

42. Zhang J, Guo L, Zhou X, Dong F, Li L, Cheng Z, et al. Dihydroartemisinin induces endothelial cell aneuploidy through the activation of the JNK signaling pathway. Oncology letters. 2016; 12: 1896-900.

43. Dong F, Han J, Jing G, Chen X, Yan S, Yue L, et al. Dihydroartemisinin transiently activates the JNK/SAPK signaling pathway in endothelial cells. Oncology letters. 2016; 12: 4699-704.

44. Anfossi L, Effert H, Albini A, Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artesminins. Pharmacogenomics J. 2006; 6: 269-78.

45. Saeed ME, Kadioglu O, Seo EJ, Greten HJ, Brenk R, Effert H. Quantitative structure-activity relationship and molecular docking of artesminin to vascular endothelial growth factor receptor 1. Anticancer research. 2015; 35: 1929-34.

46. Wei T, Jia J, Wada Y, Kapron CM, Liu J. Dose dependent effects of cadmium on tumor angiogenesis. Oncotarget. 2017; 8: 44944-59.

47. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The Vascular Endothelial Growth Factor (VEGF) Receptor Flt-1 (VEGFR-1) Modulates Flk-1 (VEGFR-2) Signaling During Blood Vessel Formation. The American Journal of Pathology. 2004; 164: 1531-5.

48. Fischer C, Mazzone M, Jonckx B, Carmeliet P, FLTI and its ligands VEGFB and PIGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008; 8: 942-56.

49. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001; 276: 26969-79.

50. Chen J, Fu Y, Day D5, Sun Y, Wang S, Liang X, et al. VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis. Nat Commun. 2017; 8: 383.

51. Jin E, Liu J, Suehiro Y, Yuan L, Okada Y, Nikolova-Krstevski V, et al. Differential roles for ETS, CREB, and EGR binding sites in mediating VEGF receptor 1 expression in vivo. Blood. 2009; 114: 5537-66.

52. Lichtenberger BM, Tan FK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGRF in tumor cells to promote epithelial cancer development. Cell. 2010; 140: 268-79.

53. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer. 2006; 119: 1519-29.

54. Hahne JC, Okuducu AF, Sahin A, Fafure V, Kiriakisid S, Wernert N. The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev Med Chem. 2008; 8: 1095-105.